Corticosteroid responsive fludarabine pulmonary toxicity

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 4, 2002, Pages 340-341

  Stoica, George S ^a   Greenberg, Harly E ^a   Rossoff, Leonard J ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Fludarabine; Interstitial pneumonitis; Pulmonary fibrosis; Pulmonary toxicity

Indexed keywords

FLUDARABINE PHOSPHATE; METHYLPREDNISOLONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HUMAN; LUNG TOXICITY; OXYGEN THERAPY; PHYSICAL EXAMINATION; PLASMAPHERESIS; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG DISEASES; MIDDLE AGED; VIDARABINE PHOSPHATE; WALDENSTROM MACROGLOBULINEMIA;

EID: 0036337633     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200208000-00003     Document Type: Article

References (6)

1. Steroid-responsive interstitial pneumonitis after fludarabine therapy
2. Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity
3. Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma
4. Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate
5. Fludarabine for prolymphocytic leukemia and risk of interstitial pneumonitis
6. Pulmonary toxicity associated with fludarabine monophosphate